Pain intensity on and off levodopa in patients with Parkinson's disease
Identifieur interne : 002160 ( Main/Exploration ); précédent : 002159; suivant : 002161Pain intensity on and off levodopa in patients with Parkinson's disease
Auteurs : Angelika Nebe [Allemagne] ; Georg Ebersbach [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-06-15.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Female, Fluctuations, Human, Humans, Levodopa, Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Pain, Pain (drug therapy), Pain (etiology), Pain Measurement, Parkinson, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Questionnaires, Severity of Illness Index, Statistics, Nonparametric, Treatment, fluctuations, nonmotor symptoms, pain, therapy.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Parkinson Disease.
- drug therapy : Pain, Parkinson Disease.
- etiology : Pain.
- Aged, Female, Humans, Male, Middle Aged, Pain Measurement, Questionnaires, Severity of Illness Index, Statistics, Nonparametric.
Abstract
Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (P = 0.001). There was a correlation (P = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22546
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000407
- to stream Istex, to step Curation: 000407
- to stream Istex, to step Checkpoint: 000D62
- to stream PubMed, to step Corpus: 001D31
- to stream PubMed, to step Curation: 001D31
- to stream PubMed, to step Checkpoint: 001C67
- to stream Ncbi, to step Merge: 002646
- to stream Ncbi, to step Curation: 002646
- to stream Ncbi, to step Checkpoint: 002646
- to stream Main, to step Merge: 002A21
- to stream PascalFrancis, to step Corpus: 000E38
- to stream PascalFrancis, to step Curation: 001E81
- to stream PascalFrancis, to step Checkpoint: 000D69
- to stream Main, to step Merge: 002E66
- to stream Main, to step Curation: 002160
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pain intensity on and off levodopa in patients with Parkinson's disease</title>
<author><name sortKey="Nebe, Angelika" sort="Nebe, Angelika" uniqKey="Nebe A" first="Angelika" last="Nebe">Angelika Nebe</name>
</author>
<author><name sortKey="Ebersbach, Georg" sort="Ebersbach, Georg" uniqKey="Ebersbach G" first="Georg" last="Ebersbach">Georg Ebersbach</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8E0991178F6949A1DE54F0A94995D4063114FFED</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22546</idno>
<idno type="url">https://api.istex.fr/document/8E0991178F6949A1DE54F0A94995D4063114FFED/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000407</idno>
<idno type="wicri:Area/Istex/Curation">000407</idno>
<idno type="wicri:Area/Istex/Checkpoint">000D62</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Nebe A:pain:intensity:on</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19412949</idno>
<idno type="wicri:Area/PubMed/Corpus">001D31</idno>
<idno type="wicri:Area/PubMed/Curation">001D31</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001C67</idno>
<idno type="wicri:Area/Ncbi/Merge">002646</idno>
<idno type="wicri:Area/Ncbi/Curation">002646</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002646</idno>
<idno type="wicri:Area/Main/Merge">002A21</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0302003</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E38</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001E81</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000D69</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Nebe A:pain:intensity:on</idno>
<idno type="wicri:Area/Main/Merge">002E66</idno>
<idno type="wicri:Area/Main/Curation">002160</idno>
<idno type="wicri:Area/Main/Exploration">002160</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pain intensity on and off levodopa in patients with Parkinson's disease</title>
<author><name sortKey="Nebe, Angelika" sort="Nebe, Angelika" uniqKey="Nebe A" first="Angelika" last="Nebe">Angelika Nebe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Movement Disorder Clinic, Beelitz‐Heilstätten</wicri:regionArea>
<wicri:noRegion>Beelitz‐Heilstätten</wicri:noRegion>
<wicri:noRegion>Beelitz‐Heilstätten</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ebersbach, Georg" sort="Ebersbach, Georg" uniqKey="Ebersbach G" first="Georg" last="Ebersbach">Georg Ebersbach</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Movement Disorder Clinic, Beelitz‐Heilstätten</wicri:regionArea>
<wicri:noRegion>Beelitz‐Heilstätten</wicri:noRegion>
<wicri:noRegion>Beelitz‐Heilstätten</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-06-15">2009-06-15</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1233">1233</biblScope>
<biblScope unit="page" to="1237">1237</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">8E0991178F6949A1DE54F0A94995D4063114FFED</idno>
<idno type="DOI">10.1002/mds.22546</idno>
<idno type="ArticleID">MDS22546</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Female</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Pain</term>
<term>Pain (drug therapy)</term>
<term>Pain (etiology)</term>
<term>Pain Measurement</term>
<term>Parkinson</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Questionnaires</term>
<term>Severity of Illness Index</term>
<term>Statistics, Nonparametric</term>
<term>Treatment</term>
<term>fluctuations</term>
<term>nonmotor symptoms</term>
<term>pain</term>
<term>therapy</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Pain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Pain</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pain Measurement</term>
<term>Questionnaires</term>
<term>Severity of Illness Index</term>
<term>Statistics, Nonparametric</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Douleur</term>
<term>Fluctuation</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (P = 0.001). There was a correlation (P = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Nebe, Angelika" sort="Nebe, Angelika" uniqKey="Nebe A" first="Angelika" last="Nebe">Angelika Nebe</name>
</noRegion>
<name sortKey="Ebersbach, Georg" sort="Ebersbach, Georg" uniqKey="Ebersbach G" first="Georg" last="Ebersbach">Georg Ebersbach</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002160 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002160 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:8E0991178F6949A1DE54F0A94995D4063114FFED |texte= Pain intensity on and off levodopa in patients with Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |